Skip to main content

Is My Product Recalled?

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Scan How It Works Saved Get Alerts

Menu

Search All Recalls Latest Recalls Scan Barcode Get Alerts

Categories

Food Recalls Medication Recalls Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other

Resources

How Recalls Work FAQ Recall Classifications Statistics & Trends About

Your Recalls

Loading...

Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

Home
/
Brands
/
MALVERN PANALYTICAL LTD Grovewood Road Malvern United Kingdom

MALVERN PANALYTICAL LTD Grovewood Road Malvern United Kingdom Recalls

All product recalls associated with MALVERN PANALYTICAL LTD Grovewood Road Malvern United Kingdom.

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

303

Class I (Serious)

34

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 981–1000 of 4747 recalls

NanoSight NS300 (Malvern) – Laser Safety Non-Compliance (2022)

Product found to not comply to Class 1 Laser safety requirement.

FDAApr 7, 2022Nationwide• MALVERN PANALYTICAL LTD Grovewood Road Malvern United Kingdom

Rifampin Injection (Mylan) – Impurity Specification (2022)

Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.

Class IIModerate

FDAApr 7, 2022Nationwide• Mylan Pharmaceuticals Inc

Cequa Cyclosporine (Sun Pharmaceutical) – Subpotent Medication (2022)

Subpotent Drug and Presence of Particulate Matter: low out-of-specification results obtained for assay and the presence of particulate matter.

1...48 495051 52...238

Page 50 of 238Next

Low

FDAApr 1, 2022Nationwide• SUN PHARMACEUTICAL INDUSTRIES INC

Travoprost Ophthalmic Solution (Mylan) – Subpotent Medication (2022)

Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related substance impurities/degradation during routine stability testing.

Class IIModerate

FDAApr 1, 2022Nationwide• Mylan Pharmaceuticals Inc

Methylprednisolone Tablets (Jubilant Cadista) – Subpotent Medication (2022)

Subpotent

FDAApr 1, 2022Nationwide• Jubilant Cadista Pharmaceuticals, Inc.

Losartan/Hydrochlorothiazide 100/12.5mg (Lupin) – AZIDO Impurity Excess (2022)

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class IIModerate

FDAMar 31, 2022Nationwide• Lupin Pharmaceuticals Inc.

Losartan/Hydrochlorothiazide 50/12.5mg (Lupin) – AZIDO Impurity Excess (2022)

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class IIModerate

FDAMar 31, 2022Nationwide• Lupin Pharmaceuticals Inc.

Losartan Potassium Tablets 50mg (Lupin) – AZIDO Impurity Excess (2022)

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class IIModerate

FDAMar 31, 2022Nationwide• Lupin Pharmaceuticals Inc.

Losartan Potassium Tablets 100mg (Lupin) – AZIDO Impurity Excess (2022)

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class IIModerate

FDAMar 31, 2022Nationwide• Lupin Pharmaceuticals Inc.

Losartan Potassium Tablets 25mg (Lupin) – AZIDO Impurity Excess (2022)

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class IIModerate

FDAMar 31, 2022Nationwide• Lupin Pharmaceuticals Inc.

Losartan/Hydrochlorothiazide 100/25mg (Lupin) – AZIDO Impurity Excess (2022)

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Class IIModerate

FDAMar 31, 2022Nationwide• Lupin Pharmaceuticals Inc.

VerifyNow P2Y12 Test (Accriva) – test result inconsistency (2022)

Two whole blood Platelet Reactivity tests exist that share the same reagent formulation and are used to obtain P2Y12 Reactivity Unit results. The test without US-FDA market clearance was distributed and it displays BASE results not displayed by the US-FDA market cleared device. A formula is being provided to health care personnel to calculate the percentage of platelet aggregation inhibition.

FDAMar 30, 2022Nationwide• Accriva Diagnostics, Inc.

IDArubicin Hydrochloride Injection (Teva) – Particulate Matter (2022)

Presence of Particulate Matter: Product was found to contain silica and iron oxide

FDAMar 29, 2022Nationwide• Teva Pharmaceuticals USA Inc

Lansoprazole Solution (Preferred Pharmaceuticals) – Stability Failure (2022)

Out of specification results observed in dissolution during long term stability testing.

Class IIModerate

FDAMar 28, 2022Nationwide• Preferred Pharmaceuticals, Inc.

VITROS FSH Reagent Pack (Ortho-Clinical) – result imprecision (2022)

Falsely high or delayed patient and QC results may occur due to low end imprecision. VITROS Immunodiagnostic Products FSH, LH and Prol Reagents Low End Imprecision. Low-level quality control (QC) and patient samples at the low end of the Measuring (Reportable) Range when using VITROS FSH, LH and Prol Reagent. Calibration failures, driven by imprecision observed with Calibrator Level 1.

FDAMar 25, 2022Nationwide• Ortho-Clinical Diagnostics, Inc

Diclofenac Sodium Topical Solution (Preferred Pharmaceuticals) – Stability Study Discontinuation ...

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Class IIModerate

FDAMar 24, 2022Nationwide• Preferred Pharmaceuticals, Inc.

Econazole Nitrate Cream (Preferred Pharmaceuticals) – Stability Study Discontinuation (2022)

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Class IIModerate

FDAMar 24, 2022CA, FL, IN• Preferred Pharmaceuticals, Inc.

Clobetasol Propionate Lotion (Preferred Pharmaceuticals) – Stability Study Discontinuation (2022)

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc. is discontinuing its stability study program.

Class IIModerate

FDAMar 23, 2022IL• Preferred Pharmaceuticals, Inc.

Symjepi Epinephrine Injection (Adamis) – Delivery System Defect (2022)

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

FDAMar 21, 2022Nationwide• Adamis Pharmaceuticals Corporation

SYMJEPI Epinephrine Injection (Adamis) – Potential Needle Clogging (2022)

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

FDAMar 21, 2022Nationwide• Adamis Pharmaceuticals Corporation